LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

CEL-SCI Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

2.51 3.29

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.4

Max

2.56

Pagrindiniai rodikliai

By Trading Economics

Pajamos

501K

-6.6M

Pelnas, tenkantis vienai akcijai

-0.096

EBITDA

-225K

-5.9M

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-14

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-4.2M

17M

Ankstesnė atidarymo kaina

-0.78

Ankstesnė uždarymo kaina

2.51

Naujienos nuotaikos

By Acuity

70%

30%

349 / 382 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

CEL-SCI Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-05-23 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

2025-05-23 21:57; UTC

Karštos akcijos

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

2025-05-23 21:15; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

2025-05-23 21:04; UTC

Įsigijimai, susijungimai, perėmimai

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

2025-05-23 20:56; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

Salesforce Back in Deal Talks With Informatica -- WSJ

2025-05-23 20:51; UTC

Svarbiausios naujienos

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

2025-05-23 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2025-05-23 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-05-23 20:41; UTC

Svarbiausios naujienos

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

2025-05-23 20:28; UTC

Svarbiausios naujienos

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

2025-05-23 20:06; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

2025-05-23 20:06; UTC

Įsigijimai, susijungimai, perėmimai

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

2025-05-23 19:50; UTC

Svarbiausios naujienos

Trump's Tariffs: Where Things Stand -- 16th Update

2025-05-23 19:28; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

2025-05-23 19:28; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

2025-05-23 19:27; UTC

Įsigijimai, susijungimai, perėmimai

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

2025-05-23 19:20; UTC

Rinkos pokalbiai

Crude Futures Post Modest Weekly Losses -- Market Talk

2025-05-23 19:18; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

2025-05-23 18:57; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

2025-05-23 18:54; UTC

Svarbiausios naujienos

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

2025-05-23 18:53; UTC

Svarbiausios naujienos
Įsigijimai, susijungimai, perėmimai

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

2025-05-23 18:52; UTC

Įsigijimai, susijungimai, perėmimai

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

2025-05-23 18:13; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-05-23 18:13; UTC

Rinkos pokalbiai

Gold Trades Higher on Reminder of Risk -- Market Talk

2025-05-23 18:00; UTC

Svarbiausios naujienos

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

2025-05-23 17:51; UTC

Rinkos pokalbiai
Uždarbis

Workday Sees Higher Bar for Guidance -- Market Talk

2025-05-23 17:42; UTC

Svarbiausios naujienos

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

2025-05-23 17:39; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

2025-05-23 17:07; UTC

Svarbiausios naujienos

Trump's Tariffs: Where Things Stand -- 15th Update

2025-05-23 17:04; UTC

Rinkos pokalbiai
Uždarbis

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Akcijų palyginimas

Kainos pokytis

CEL-SCI Corp Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

0

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 0.2494Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

349 / 382 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Meškų rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

$

Apie bendrovę CEL-SCI Corp

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.